Larimar Therapeutics Submits First BLA Module for Nomlabofusp Accelerated Approval with Positive Long-Term Data

summarizeSummary

Larimar Therapeutics submitted the first module of its BLA for accelerated approval of nomlabofusp for Friedreich's ataxia, supported by positive long-term clinical data and FDA alignment on the submission package.

check_boxKey Events · Product Development and Regulatory · LRMR

• BLA Submission Initiated

  Larimar Therapeutics submitted the first module of its rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia. Remaining modules are expected in 2H 2026.

• Positive Long-Term Clinical Data

  The ongoing open-label study showed sustained increases in skin frataxin (FXN) levels, with 100% of participants achieving levels comparable to asymptomatic carriers at one year. Directional improvements were also observed across multiple clinical outcome measures (mFARS, FARS-ADL, 9-HPT, MFIS) compared to a natural history reference population.

• FDA Alignment on Accelerated Approval Pathway

  The FDA confirmed in pre-BLA meeting minutes that the existing data package appears sufficient to support a BLA submission seeking accelerated approval, and reaffirmed willingness to consider FXN as a novel surrogate endpoint.

• Confirmatory Phase 3 Study Planned

  Dosing of the first patient in a global confirmatory Phase 3 study is expected in Q3 2026, enrolling ambulatory patients aged 2-40.

auto_awesomeAnalysis · LRMR · Life Sciences

Larimar Therapeutics has reached a critical regulatory milestone by submitting the first module of its rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp for Friedreich's ataxia. This follows positive long-term data from an open-label study, which showed sustained increases in frataxin (FXN) levels in 100% of participants at one year, comparable to asymptomatic carriers. Crucially, the FDA has indicated that the existing data package appears sufficient to support the BLA submission, including the use of skin frataxin as a novel surrogate endpoint. The data also showed directional improvements in multiple clinical outcome measures compared to a natural history reference population, with one non-ambulatory patient becoming ambulatory. While anaphylaxis events were reported, they were generally well-tolerated. This submission and supporting data significantly de-risk the development program and move the company closer to potentially launching the first disease-modifying therapy for Friedreich's ataxia by mid-2027.